Search

314 results for "lecanemab".

Research summaries 285

Showing the best 200 of 285, 151–160, page 16 of 20. Filter these by subject, year and score in the research library →

1. Nieuwe geneesmiddelen bij Alzheimer - UpdateResearch summary

   Research summaries · alzhub.org/study/nieuwe-geneesmiddelen-bij-alzheimer-update-69d2f1b5

   Met de registratie van lecanemab in april 2025 en donanemab in september 2025 komt slechts voor een klein deel van de patiënten in het beginstadium van de ziekte van Alzheimer een mogelijke therapie binnen bereik. Echter, de …

2. Quantitative systems pharmacology-based exploration of relevant anti-amyloid therapy challenges in clinical practiceResearch summary

   Research summaries · alzhub.org/study/quantitative-systems-pharmacology-based-exploration-of-relevant-anti-38774587

   … and 6 to 20 months for lecanemab, aducanumab, and donanemab, respectively, for baseline central amyloid values between 50 and 200 Centiloids (CL). Changes in plasma cerebrospinal fluid Aβ42 and the plasma Aβ42/ Aβ40 ratio-fluid …

3. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implicationsResearch summary

   Research summaries · alzhub.org/study/risk-factors-in-developing-amyloid-related-imaging-abnormalities-aria-38312931

   … death. By analyzing lecanemab, aducanumab, gantenerumab, donanemab, and bapineuzumab clinical trials; risk factors for developing ARIA can be identified to mitigate some of the ARIA risk. Risk factors for developing ARIA-E are a …

4. Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectivesResearch summary

   Research summaries · alzhub.org/study/second-generation-anti-amyloid-monoclonal-antibodies-for-alzheimer-s-39865265

   … aducanumab (Aduhelm®), lecanemab (Leqembi®), and donanemab (Kisunla™). Notably, lecanemab received traditional approval after demonstrating clinical benefit, supporting the Aβ cascade hypothesis. These MABs targeting Aβ are …

5. The controversy around anti-amyloid antibodies for treating Alzheimer's disease : The European Medical Agency's ruling against the latest anti-amyloid drugs highlights the ongoing debate about their safety and efficacyResearch summary

   Research summaries · alzhub.org/study/the-controversy-around-anti-amyloid-antibodies-for-treating-alzheimer-39443750

   The recent rejection of lecanemab by the European Medicines Agency despite its approval in other countries highlights the debate among researchers and regulatory bodies about the efficacy, safety, and underlying scientific basis …

6. Therapeutic monoclonal antibodies targeting amyloid beta in Alzheimer disease current evidence clinical outcomes limitations and future directionsResearch summary

   Research summaries · alzhub.org/study/therapeutic-monoclonal-antibodies-targeting-amyloid-beta-in-alzheimer-0a449f11

   … aggregated forms, and lecanemab preferentially recognizes protofibrils. Donanemab selectively targets deposited amyloid plaques. Recent regulatory approvals of aducanumab, lecanemab, and donanemab demonstrate significant plaque …

7. Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?Research summary

   Research summaries · alzhub.org/study/tracking-neuroinflammatory-biomarkers-in-alzheimer-s-disease-a-39080712

   … antibodies, including lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have limited clinical benefits and their use comes with a significant risk of serious adverse events. Indeed, in our review, …

8. [Anti-Amyloid Antibody Therapy for Alzheimer's Disease]Research summary

   Research summaries · alzhub.org/study/anti-amyloid-antibody-therapy-for-alzheimer-s-disease-39370836

   … efficacy of aducanumab, lecanemab, and donanemab in these patients. Lecanemab showed selectivity towards protofibrils over fibrils, and donanemab was specifically directed against Aβ only in brain-specific amyloid plaques. In …

9. [Antibody therapy in Alzheimer's disease]Research summary

   Research summaries · alzhub.org/study/antibody-therapy-in-alzheimer-s-disease-42714614

   … and neurodegeneration. Lecanemab and donanemab, are the first disease-modifying antibodies available for early Alzheimer's disease. Both reduce Aβ plaques and slow cognitive decline. Lecanemab targets soluble protofibrils and …

10. A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's diseaseResearch summary

    Research summaries · alzhub.org/study/a-new-era-in-neuropharmacology-assessing-the-efficacy-and-safety-of-42084750

    … monoclonal antibodies such as lecanemab and donanemab have shown high amyloid plaque clearance and reduced cognitive deterioration. Nevertheless, the treatments are associated with amyloid-related imaging abnormalities (ARIA). In …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

28781 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-06. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.